Edition:
United States

Clearside Biomedical Inc (CLSD.OQ)

CLSD.OQ on NASDAQ Stock Exchange Global Market

10.36USD
22 Jun 2018
Change (% chg)

$0.04 (+0.39%)
Prev Close
$10.32
Open
$10.32
Day's High
$10.36
Day's Low
$10.10
Volume
714,837
Avg. Vol
236,939
52-wk High
$15.27
52-wk Low
$5.32

Select another date:

Wed, May 9 2018

BRIEF-Clearside Biomedical Q1 Loss Per Share $0.62

* CLEARSIDE BIOMEDICAL ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Clearside Biomedical Reports Q4 Loss Per Share $0.65

* CLEARSIDE BIOMEDICAL ANNOUNCES FOURTH QUARTER 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Clearside Proposes Public Offering Of $75 Mln Of Shares

* CLEARSIDE ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Clearside Biomedical Provides Update On Two Phase 3 Clinical Trials Of CLS-TA In Retinal Vein Occlusion

* CLEARSIDE BIOMEDICAL PROVIDES UPDATE ON TWO PHASE 3 CLINICAL TRIALS OF CLS-TA IN RETINAL VEIN OCCLUSION

UPDATE 2-Clearside Biomedical's shares surge as eye drug succeeds in trial

* Shares surge 50 pct (Adds comments from analyst and conference call, background; updates share movement)

Clearside Biomedical's eye treatment succeeds study, shares surge

Drug developer Clearside Biomedical Inc said on Monday its treatment helped improve vision in patients with fluid buildup in the eye in a late-stage study, sending its shares surging 54.1 percent in premarket trading.

Clearside Biomedical's eye treatment succeeds late-stage study

March 5 Clearside Biomedical Inc said on Monday its treatment for fluid build-up in the eye had met the main goal of a late-stage study.

Select another date: